Daniel Ebner
Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Recent publications
-
Author Correction: C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption.
Journal article
Sharma AB. et al, (2023), Nature communications, 14
-
Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study.
Journal article
Bešević J. et al, (2023), Journal of epidemiology and community health
-
Selective ROCK Inhibitor Enhances Blood Flow Recovery after Hindlimb Ischemia
Journal article
Fayed HS. et al, (2023), International Journal of Molecular Sciences, 24, 14410 - 14410
-
Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells
Journal article
Athanasiadis P. et al, (2023), iScience, 26
-
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
Journal article
Wei J. et al, (2023), Nature Communications, 14